Bausch & Lomb Corp
Company Profile
Business description
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Contact
520 Applewood Crescent
VaughanONL4K 4B4
CANT: +1 905 695-7700
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,500
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,530.90 | 316.70 | -4.04% |
| CAC 40 | 7,274.95 | 324.03 | -4.26% |
| DAX 40 | 20,641.72 | 1,075.67 | -4.95% |
| Dow JONES (US) | 38,445.03 | 2,100.90 | -5.18% |
| FTSE 100 | 8,054.98 | 419.76 | -4.95% |
| HKSE | 20,404.62 | 2,445.19 | -10.70% |
| NASDAQ | 15,604.17 | 946.44 | -5.72% |
| Nikkei 225 | 31,744.71 | 2,035.87 | -6.03% |
| NZX 50 Index | 11,833.52 | 391.76 | -3.20% |
| S&P 500 | 5,084.85 | 311.67 | -5.78% |
| S&P/ASX 200 | 7,356.40 | 311.40 | -4.06% |
| SSE Composite Index | 3,130.17 | 211.84 | -6.34% |